Pneumocystis jirovecii pneumonia (PJP) is increasingly seen in association with the use of new and potent immunosuppressive therapies in populations not infected with human immunodeficiency virus. Today, molecular methods are widely used to improve diagnostic yield; however, the relationship between clinical findings and quantitative polymerase chain reaction (qPCR) results is undefined. Our objective was to describe characteristics of PJP in patients with malignancies and determine if qPCR results were correlated with clinical findings. From 2007 to 2012, all patients at the Peter MacCallum Cancer Centre with positive Pneumocystis PCR were identified from a microbiology database. Clinical, radiological, and microbiological records were reviewed. PJP was defined as the presence of positive PCR for Pneumocystis on a respiratory specimen, radiological abnormalities consistent with a pneumonic process, and receipt of targeted PJP treatment. qPCR was performed on all diagnostic specimens, and values were reported according to clinical findings. Forty-five patients fulfilled inclusion criteria: 44.4% had underlying solid organ tumors and 55.6% had hematological malignancies. Nonsmall cell lung carcinoma and lymphoma were the most frequent predispositions. Shortness of breath, cough, and fever were reported in 64.4%, 48.9%, and 42.2% of the patients, respectively. Admission to the intensive care unit and mortality rates were lower than in previous reports. Overall, a relationship between other clinical features and qPCR results was not identified. In the era of routine molecular diagnostics, patients with malignancy and PJP have improved outcomes. However, there was no demonstrable relationship between qPCR results and clinical features or PCR data and outcomes.
Introduction
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection seen increasingly in immunocompromised patient populations not infected with human immunodeficiency virus (HIV) [1] . Microbiological methods of diagnosis (immunofluorescence or staining) are limited by the requirement for staff expertise and poor negative predictive value. Polymerase chain reaction (PCR)-based techniques are more sensitive and specific than microbiological methods and may increase diagnostic positive results by up to five-fold [2, 3] . Furthermore, quantitative PCR (qPCR) enables evaluation of fungal burden in clinical specimens, and some have proposed the use of qPCR for distinguishing Pneumocystis colonization from infection with the use of cutoff values [4, 5] .
In high-risk patients with an illness consistent with PJP (e.g., pneumonia syndrome with diffuse pulmonary infiltrate), the relationship between qPCR and clinical features (e.g., disease severity) has not been evaluated, nor has the prognostic significance of fungal burden been explored. Thus, the contribution of qPCR results to the final diagnosis and patient management remains uncertain. Previously we described features of PJP in hematology-oncology patients; however, this was prior to the era of routine molecular testing for the diagnosis of PJP [6] . The objectives of this study were to describe the clinical features and outcomes of PJP in patients with hematological malignancies or solid tumors and to determine if qPCR results correlated with clinical features of PJP in this target population.
Methods

Study population and definitions
The Peter MacCallum Cancer Centre (PMCC) is a quaternary referral center for patients with a range of hematological malignancies and solid tumors. For the current study, a laboratory database was used to identify all patients managed at PMCC from 2007 to 2012 and who tested positive for P. jirovecii by PCR as performed by the Victorian Infectious Diseases Reference Laboratory (VIDRL).
Patients were included in the study if they had a confirmed diagnosis of PJP based on PCR testing of a respiratory specimen (sputum or bronchoalveolar lavage [BAL]), radiological abnormality consistent with a pneumonic process, and receipt of targeted antibiotic therapy for PJP. Clinical and radiological records of eligible patients were reviewed using a standardized form that included descriptions of patient demographics, underlying malignancy, clinical presentation, presence or absence of risk factors, intensity of management, and all-cause death within 30 days. In addition, the nature of diagnostic specimen was recorded (sputum or BAL), and copathogens were documented. Deidentified data were presented to blinded reviewers (n = 3) who were requested to determine the likelihood of PJP diagnosis on the basis of clinical and predisposing characteristics. Reviewers were independent of the study and were clinicians in the fields of hematology and infectious diseases. This study was consistent with institutional ethics committee policy providing consent waiver for retrospective audit activities.
Diagnostic evaluation
During the study period, the decision to perform sputum or BAL diagnostic evaluation was made by the treating physician. Bronchoscopy and BAL collection were performed according to a standardized protocol. Briefly, the BAL procedure involved sequential instillation of three to six aliquots (20 ml each) of sterile saline (up to a maximum of 180 ml) into the right middle lobe or the lung subsegment with the most prominent infiltrate seen on chest x-ray or computed tomography with subsequent recovery. Sputum collection was noninduced. All initial diagnostic samples were tested with the Light Cycler (version 2.0; Roche Diagnostics, Mannheim, Germany), using a real-time touch-down PCR assay to target the P. jirovecii major surface glycoprotein (MSG) genes, performed as described by Larsen et al. [7] . Because a cloned MSG template was not available to our laboratory for generation of the standard curve, quantitation of organism burden by PCR was determined using serial 10-fold dilutions on known positive P. jirovecii respiratory samples. The samples were processed for modified toluidine blue staining according to the method described by Gosey et al. [8] , and stained cyst forms were counted serially by an experienced microscopist. The same 10-fold serial dilutions were subsequently tested in the PCR assay, and a standard curve was generated by comparing PCR cycle threshold values with the number of Pneumocystis cysts per milliliter.
Analysis
Characteristics of patients with PJP were summarized as proportional outcomes. The range of P. jirovecii PCR thresholds (organism quantitation) associated with selected patient and radiological and microbiological factors were determined. Patients were subsequently classified as having quantifiable or nonquantifiable (below the limit of accurate quantitation) P. jirovecii by PCR. Categorical variables were compared using the χ 2 test, with P ≤ 0.05 deemed statistically significant. Analyses were performed using Prism software (version 6.0, Graphpad Inc., San Diego, CA, USA).
Results
Characteristics of patients with PJP
Forty-five patients fulfilled inclusion criteria and were assessed by blinded reviewers as unlikely to have an alternative diagnosis (i.e., other than PJP) accounting for clinical and radiological abnormalities. Median age of patients with PJP was 63 years (range, 23-85), and the majority (68.9%) were male, as summarized in Table 1 In 22 cases (48.9%), PJP diagnosis was confirmed by PCR analysis of sputum, and in 23 cases, diagnosis was established with BAL specimens. In 34 patients, a potential copathogen was identified. In the majority of instances (73.3%, 33/45), ground glass opacities or infiltrates were evident on radiological imaging. The rate of admission into the intensive care unit (ICU) was 20.0%, and the overall mortality rate was 6.7% (3/45).
Correlation between clinical features and qPCR
qPCR results (median, range) were determined for type of diagnostic specimen, underlying malignancy, clinical features of PJP, and outcomes following Pneumocystis infection (see Table 2 ). Further analysis of patients with quantifiable and nonquantifiable organism burden (0 cysts/ml) and PCR positivity was also performed. These subgroups are compared in Table 3 . There were no significant differences between the two patient groups, with the exception of the higher proportion of patients investigated using sputum analysis with quantifiable P. jirovecii.
Discussion
Pneumocystis infection has been increasingly detected in patients not infected with HIV, particularly related to use of newer and potent immunosuppressive therapies and improved sensitivity of molecular diagnostic methods [9, 10] . Our findings (Table 1) indicate that measures for prevention and early detection are required for patients with malignancy, particularly nonsmall cell lung carcinoma (NSCLC) and lymphoma.
Historically, PJP in non-HIV-immunosuppressed populations has been associated with a more acute clinical onset and higher rates of respiratory failure that often required intensive care management [11, 12] than in HIV-infected populations. One 10-year review demonstrated ICU admission rates of up to 70% [11] , and reported mortality rates have been 21%-39% [10, 12] . The most common presenting symptom was shortness of breath (64.4%), followed by cough (48.9%) and fever (42.2%). Only 13.3% of patients described the constellation of all three symptoms. These rates are lower than those reported in previous studies [10, 11, 13] . Compared with earlier reports [12] , lower rates of ICU admission (20.0%) and mortality (6.7%) were observed. Improved outcomes may be associated with earlier detection and treatment through routine use of sensitive molecular diagnostic methods [14] .
With respect to predisposing factors, 26.7% of our reported PJP cases were administered corticosteroids prior to presentation with Pneumocystis infection, which is lower than the range reported by other researchers (30%-65%) [10, 12] . The use of high-dose corticosteroids, with their impact on T-cell immunity, is a well-recognized predisposition for PJP [15] . However, other immune deficits, including impairment in humoral immunity, are increasingly recognized as new risk factors for PJP [1] . It is likely that a number of factors contribute to the overall risk of developing Pneumocystis infection, and complex risk assessment is therefore required.
Higher median organism burden was found in our patients with PJP who were investigated by collection of sputum specimens. This is consistent with the trend described by Matsumura et al. [16] . One explanation for this finding is that the treating physicians may have opted for noninvasive diagnostic evaluation (sputum collection) in acutely ill patients. Another explanation could be that BAL specimen collection and processing (e.g., dilution of BAL due to instilled saline volume at time of bronchoscopy) affected quantifiable results. Clinical spectrum of disease and patient outcomes were not correlated with qPCR results. This could be a reflection of a lower overall organism burden and the range of factors that contribute to the spectrum of immunosuppression seen in our non-HIV studied population [17] .
The increased sensitivity of PCR-based diagnostic methods compared with traditional staining methods has led to identification of a group of patients with positive PCR results but negative staining [2] . Some studies have attempted to define this population, proposing the use of qPCR cutoffs to distinguish between clinical infection and colonization [4, 5] . Notably, findings from our study demonstrated that patients with higher or lower burden of P. jirovecii by PCR were clinically indistinguishable. The lower sensitivity of staining methods, lower overall organism burden, and differential levels of immunosuppression in our patient group may account for these findings. Metaanalysis of PCR diagnosis of PJP has suggested that 31.8% of patients labeled with false-positive PCR results had or later developed PJP [2] , highlighting the fact that patients with a positive PCR require careful follow-up and/or treatment.
Our study has several limitations. Our method of standard curve generation involved the use of microscopically documented cyst counts, which may result in reduced sensitivity. This differs from methods used in other reported studies of qPCR with MSG targets and limits direct comparisons [4] . Recent publications illustrate the lack of laboratory method standardization [4, 5, 18] . As we did not use cloned MSGs to generate our standard curve for quantitation, we were unable to define a cutoff for infection. However, we believe our unit of quantitation (cysts/ml) is still a useful reflection of organism burden and allows analysis of its correlation with clinical findings and outcomes. The retrospective nature of data collection limited our ability to obtain further information such as the duration of symptoms prior to presentation and timeliness of diagnosis with respect to commencement of PJP treatment. We did not compare our patient population with other at-risk populations (e.g., HIV-infected patients), and our findings may not be directly applicable to general hospital patients or patients who are immunocompromised due to other underlying conditions.
In summary, we report features of PJP in patients with hematological and solid tumor malignancies at an Australian cancer treatment center. A range of predisposing conditions was identified, with NSCLC and lymphoma most frequently identified. Rates of respiratory compromise, ICU management, and deaths were lower than those described in previous reports. Our findings do not demonstrate correlation between qPCR and underlying malignancy, clinical features of PJP, or outcomes. While PCR is an important tool to aid in the overall assessment of an immunocompromised patient with potential Pneumocystis infection, it may not distinguish severity of disease or have prognostic implications.
